MX388726B - Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. - Google Patents
Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.Info
- Publication number
- MX388726B MX388726B MX2019007338A MX2019007338A MX388726B MX 388726 B MX388726 B MX 388726B MX 2019007338 A MX2019007338 A MX 2019007338A MX 2019007338 A MX2019007338 A MX 2019007338A MX 388726 B MX388726 B MX 388726B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- cognitive impairment
- compositions
- containing gaba
- age
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436272P | 2016-12-19 | 2016-12-19 | |
| PCT/IB2017/001762 WO2018130868A1 (en) | 2016-12-19 | 2017-12-20 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| PCT/IB2017/001763 WO2018130869A1 (en) | 2016-12-19 | 2017-12-20 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007338A MX2019007338A (es) | 2019-09-19 |
| MX388726B true MX388726B (es) | 2025-03-20 |
Family
ID=62557208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007338A MX388726B (es) | 2016-12-19 | 2017-12-20 | Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180170941A1 (enExample) |
| EP (1) | EP3555100B1 (enExample) |
| JP (1) | JP7153938B2 (enExample) |
| CN (2) | CN116640143A (enExample) |
| AU (1) | AU2017393082B2 (enExample) |
| CA (1) | CA3047684A1 (enExample) |
| EA (1) | EA201991497A1 (enExample) |
| IL (1) | IL267451B2 (enExample) |
| MX (1) | MX388726B (enExample) |
| WO (2) | WO2018130868A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4032889A1 (en) | 2013-12-20 | 2022-07-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| MA42624A (fr) | 2015-06-19 | 2021-04-28 | Agenebio Inc | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN112601749B (zh) * | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| EP4077333A4 (en) * | 2019-12-19 | 2024-01-10 | Agenebio, Inc. | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE IMPAIRMENT |
| US20220062296A1 (en) * | 2020-07-10 | 2022-03-03 | Agenebio, Inc. | Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment |
| AU2021304355A1 (en) * | 2020-07-10 | 2023-03-02 | Agenebio, Inc. | Polymorphs of a GABA |
| CN113413532B (zh) * | 2021-07-01 | 2022-03-01 | 曾迎春 | 基于虚拟现实的癌症相关认知障碍评估与康复训练系统 |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| NL7305644A (enExample) | 1972-04-20 | 1973-10-23 | ||
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| DK0402644T3 (da) | 1989-05-19 | 1996-01-02 | Hoechst Roussel Pharma | N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| JP4099224B2 (ja) | 1994-03-02 | 2008-06-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | 舌下又はバッカル医薬組成物 |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| KR100694682B1 (ko) | 1999-03-03 | 2007-03-13 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-치환 피페리딘 유도체 불화물 |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| AU2003274353B2 (en) | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| CN1829804A (zh) | 2002-11-22 | 2006-09-06 | 约翰斯·霍普金斯大学 | 治疗认知功能障碍的靶位 |
| ATE411015T1 (de) | 2003-10-22 | 2008-10-15 | Merz Pharma Gmbh & Co Kgaa | Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien |
| WO2006040038A1 (en) | 2004-10-12 | 2006-04-20 | F.Hoffmann-La Roche Ag | Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders |
| CA2584757C (en) | 2004-10-20 | 2012-07-03 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| JP4783375B2 (ja) * | 2004-10-20 | 2011-09-28 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾベンゾジゼピン誘導体 |
| DE602005007265D1 (de) | 2004-12-14 | 2008-07-10 | Hoffmann La Roche | Tetrazyklische imidazobenzodiazepine als gaba-rezeptormodulatoren |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| WO2007019312A2 (en) | 2005-08-03 | 2007-02-15 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| AU2009277086B2 (en) | 2008-08-01 | 2015-12-10 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| CN102223790B (zh) | 2008-09-25 | 2015-11-25 | 维乌作物保护有限公司 | 生产聚合物纳米颗粒的方法和活性成分的制剂 |
| JP2013516497A (ja) | 2010-01-11 | 2013-05-13 | ミスリィディオン，インク． | 認知増強のための化合物と組成物、製造方法、および治療方法 |
| SG10201509163VA (en) | 2010-11-05 | 2015-12-30 | Hoffmann La Roche | Use Of Active Pharmaceutical Compounds For The Treatment Of Central Nervous System Conditions |
| BR112013012072A2 (pt) * | 2010-11-15 | 2016-08-16 | Agenebio Inc | derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US20150224094A1 (en) | 2012-09-10 | 2015-08-13 | Ophirex, Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| EP4032889A1 (en) * | 2013-12-20 | 2022-07-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| MA42624A (fr) * | 2015-06-19 | 2021-04-28 | Agenebio Inc | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
| CN112601749B (zh) * | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 |
| EP4077333A4 (en) * | 2019-12-19 | 2024-01-10 | Agenebio, Inc. | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE IMPAIRMENT |
-
2017
- 2017-12-19 US US15/847,906 patent/US20180170941A1/en not_active Abandoned
- 2017-12-20 JP JP2019554038A patent/JP7153938B2/ja active Active
- 2017-12-20 MX MX2019007338A patent/MX388726B/es unknown
- 2017-12-20 WO PCT/IB2017/001762 patent/WO2018130868A1/en not_active Ceased
- 2017-12-20 CN CN202310213936.1A patent/CN116640143A/zh active Pending
- 2017-12-20 WO PCT/IB2017/001763 patent/WO2018130869A1/en not_active Ceased
- 2017-12-20 CA CA3047684A patent/CA3047684A1/en active Pending
- 2017-12-20 IL IL267451A patent/IL267451B2/en unknown
- 2017-12-20 AU AU2017393082A patent/AU2017393082B2/en active Active
- 2017-12-20 EP EP17891696.1A patent/EP3555100B1/en active Active
- 2017-12-20 CN CN201780086584.0A patent/CN110382501A/zh active Pending
- 2017-12-20 EA EA201991497A patent/EA201991497A1/ru unknown
-
2022
- 2022-09-02 US US17/902,374 patent/US20230134844A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201991497A1 (ru) | 2020-01-20 |
| CN110382501A (zh) | 2019-10-25 |
| CA3047684A1 (en) | 2018-07-19 |
| CN116640143A (zh) | 2023-08-25 |
| JP2020512389A (ja) | 2020-04-23 |
| NZ755287A (en) | 2025-06-27 |
| US20180170941A1 (en) | 2018-06-21 |
| IL267451B1 (en) | 2023-06-01 |
| WO2018130869A1 (en) | 2018-07-19 |
| IL267451B2 (en) | 2023-10-01 |
| MX2019007338A (es) | 2019-09-19 |
| WO2018130868A8 (en) | 2019-08-08 |
| AU2017393082B2 (en) | 2022-04-21 |
| IL267451A (en) | 2019-08-29 |
| EP3555100A4 (en) | 2020-06-10 |
| EP3555100A1 (en) | 2019-10-23 |
| US20230134844A1 (en) | 2023-05-04 |
| JP7153938B2 (ja) | 2022-10-17 |
| WO2018130868A1 (en) | 2018-07-19 |
| AU2017393082A1 (en) | 2019-07-25 |
| EP3555100B1 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388726B (es) | Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. | |
| MX381561B (es) | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. | |
| MX2020013374A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| MX2020013927A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. | |
| MX2022007725A (es) | Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. | |
| AU2019268069A1 (en) | Methods and compositions for improving cognitive function | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| MX376257B (es) | Moduladores alostericos de receptores de acetilcolina nicotinicos. | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
| JP2020186274A5 (enExample) | ||
| MX2023000405A (es) | Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo. | |
| IN2013DN11328A (enExample) | ||
| JOP20200272A1 (ar) | مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية | |
| MX2025001992A (es) | Derivados de benzazepina, composiciones y métodos para tratar deterioro cognitivo | |
| EA201691290A1 (ru) | Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения | |
| NZ776101B2 (en) | Extended release pharmaceutical compositions of levetiracetam | |
| NZ776101A (en) | Extended release pharmaceutical compositions of levetiracetam | |
| NZ755287B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK1192413A (en) | Methods and compositions for improving cognitive function | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| HK1220364A1 (zh) | 用於改善認知功能的方法和組合物 | |
| EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
| GR1009498B (el) | Πολλαπλων φαρμακολογικων στοχων, αμινο-τετραϋδρο-φουρανια κατα νευροεκφυλιστικων και νευροαναπτυξιακων ασθενειων, σχιζοφρενειας και καταθλιψης | |
| GR1009143B (el) | Πρωτοτυπη θεραπευτικη δραση επιλεγμενων αμινοτετραϋδροφουρανιων κατα των νευροεκφυλιστικων και των διαχυτων νευροαναπτυξιακων ασθενειων |